A 47-year-old woman with a history of metastatic neuroendocrine carcinoid tumor (NET) status in remission after liver transplant was hospitalized for workup of a new pancreatic mass concerning for recurrence. Several days into her hospital course, she developed acute-onset severe bilateral periorbital swelling, chemosis, and ophthalmoplegia as well as occasional flushing and palpitations. Her best-corrected visual acuity was 20/70 in both eyes. Pupils, intraocular pressure, and color vision were normal. She had bilateral proptosis to 20/21 mm by Hertel exophthalmometer, −3 restriction of extraocular movements in all directions of gaze, diffuse punctate epithelial erosions, and mechanical lower lid entropion secondary to severe chemosis in both eyes (Figure 1A). Anterior segment examination and dilated ophthalmoscopy results were otherwise unremarkable.
Please finish quiz first before checking answer.
Read the answer below and download your certificate.
Read the discussion below and retake the quiz.
Recurrent NET metastatic to the EOMs
C. Biopsy the EOMs
NETs are rare neoplasms that arise in the intestine, pancreas, or lungs and can cause hormone hypersecretory syndromes. NETs most commonly metastasize to the liver, followed by bone and lung1; metastasis to the EOMs is uncommon. Most reports describe unilateral involvement; rarely is there bilateral symmetric enlargement of all muscles as seen in this patient.2,3 Patients may develop proptosis, diplopia, motility limitations, eyelid swelling, and optic disc edema.4 Treatment options include excision, exenteration, radiotherapy, hormonal therapy, and chemotherapy.5
The next best step is EOM biopsy (choice C) to confirm neoplastic involvement and eliminate alternative etiologies such as myositis or orbital inflammatory disease. Thyroid eye disease often shows tendon-sparing EOM enlargement, but given the extent of involvement and negative thyroid serologies, this diagnosis is unlikely (choice A). Furthermore, corticosteroids may affect diagnostic yield and should be avoided prior to biopsy.6 PET/CT imaging (choice B) may identify additional metastases and areas of disease activity more accessible for biopsy, but would not provide tissue diagnosis and is not the next best step. Treatment with octreotide for NET metastases (choice D) is appropriate only after disease recurrence is confirmed.
Sign in to take quiz and track your certificates
JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 Credit(s)™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC
CME Disclosure Statement: Unless noted, all individuals in control of content reported no relevant financial relationships. If applicable, all relevant financial relationships have been mitigated.
Corresponding Author: Katherine M. Lucarelli, MD, Department of Ophthalmology, University of Illinois at Chicago, 1855 W Taylor St, Chicago, IL 60612 (email@example.com).
Published Online: May 5, 2022. doi:10.1001/jamaophthalmol.2022.0265
Conflict of Interest Disclosures: None reported.
Additional Contributions: We thank the patient for granting permission to publish this information.
You currently have no searches saved.
You currently have no courses saved.